SENORES
NSESenores Pharmaceuticals Limited (SMALL CAP)
Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹1,290.00
129.30 (11.14%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹5.94K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
44.0
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹513+151.5%
52W High₹1,296-0.5%
Current Price
₹1,290.00
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹1,032.00
Upper Circuit₹1,548.00
Reference Price
₹1,290.00
Investment Checklist
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹821.4
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹908.35
3-day momentum: +17.9% — strong upward pressure
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Composite score 50.21 (BUY) with 55.0% confidence
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
55%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
1082.65
EMA50
994.74
EMA200
830
Price Action
MIXED
NEUTRAL
Higher Highs5
Higher Lows5
Lower Highs4
Lower Lows4
Support & Resistance Levels
Resistance (Above)
No recent resistance detected
Support (Below)
₹1194.40
₹1173.80
₹946.10
₹906.60
₹877.02
Volume Analysis
TrendDECREASING
Change-34.50%
Unusual VolumeNo
Divergence Detected
Bearish (price up, volume down)
Recent MA Crossovers
10/20 Bearish Cross
3 days ago
SELL
Stop Loss Levels
Fixed Risk
1% Risk₹1277.10
3% Risk₹1251.30
5% Risk₹1225.50
7% Risk (Custom)
₹1199.70Technical Levels
1x ATR (Volatility)₹1226.60
2x ATR (Swing)₹1163.20
3x ATR (Trend)₹1099.80
Immediate Support₹1194.40
Moving Averages
EMA 9 (Short-term)₹1128.57
EMA 20 (Medium-term)₹1082.65
EMA 50 (Trend)₹994.74
EMA 200 (Long-term)₹830.00
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹98.8 Cr | ₹130.3 Cr | ₹153.4 Cr | ₹164.9 Cr |
| Net Profit | ₹17.8 Cr | ₹19.7 Cr | ₹32.4 Cr | ₹31.7 Cr |
| EPS | — | ₹4.60 | ₹6.54 | ₹7.29 |
| Operating Profit | ₹30 Cr | ₹37.5 Cr | ₹54.9 Cr | ₹57.8 Cr |
ROE
7.45%
ROCE
8.26%
Debt/Equity
0.40
Current Ratio
3.00
OPM
35.06%
NPM
19.21%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for SENORES
View All
negative
CNBC TV18 - Markets 30d ago
Senores Pharma Q4 Results: Stock drops 5% on sequential earnings weakness
Senores Pharmaceuticals shares fell over 5% despite strong year-on-year earnings growth, as investors reacted to sequential weakness in EBITDA and margins amid a softer operational performance in the March quarter.
MOGSECSENORESFinancial ServicesHealthcare